Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001465636 | SCV001669626 | likely benign | Hereditary breast ovarian cancer syndrome | 2020-08-05 | criteria provided, single submitter | clinical testing | |
Genetics and Molecular Pathology, |
RCV002272472 | SCV002556805 | likely benign | Familial cancer of breast | 2020-05-25 | criteria provided, single submitter | clinical testing | The BRCA2 c.10013C>A variant is classified as Likely Benign (BS2, BP6) Rebbeck 2016 excluded PTC variants after codon 3010 and did not define as pathogenic; ENIGMA criteria (2017) - variants downstream of position 3326 "unlikely clinically relevant". Case-control and frequency data indicate that BRCA2 c.9976A>T (p.Lys3326Ter) does not confer a high risk of cancer (OR 1.3-1.5, dependent on breast or ovarian cancer subtype (Meeks et al., 2016; J Natl Cancer Inst 108), demonstrating that residues at and downstream of 3327 are likely dispensable. |
Gene |
RCV003327517 | SCV004034935 | uncertain significance | not provided | 2023-03-10 | criteria provided, single submitter | clinical testing | Not observed at significant frequency in large population cohorts (gnomAD); Nonsense variant predicted to result in protein truncation as the last 81 amino acids are lost; Located in a region that tolerates variation and lacks pathogenic variants; Has not been previously published as pathogenic or benign to our knowledge; Also known as 10241C>A |
Ambry Genetics | RCV004038643 | SCV005023831 | likely benign | Hereditary cancer-predisposing syndrome | 2023-10-25 | criteria provided, single submitter | clinical testing | This alteration is classified as likely benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. |